Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 17.04 · opened flat. High/low 17.04 at 9:30 am ET, 17.03 at 10:15 am ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of TBPH revenue | Skew |
|---|---|---|---|
| VTRSViatris Inc. | 0.26% | 35.00% | 133× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“While Viatris Inc. ("Viatris") records the total net sales of YUPELRI within its own financial statements, our implied 35% YUPELRI revenue, as compared to the prior year period, was as follows:”
$38M relationship133× more of TBPH’s book than VTRS’s
basisTBPH fy2025 · closed 2025-12 $107MVTRS fy2025 · closed 2025-12 $14.3B
FILING10-K0001104659-26-033077cik 0001583107
“Viatris is the NDA holder and is responsible for manufacturing, pricing and compliance matters as well as sales and marketing in the community setting.”
FILING10-K0001104659-26-033077cik 0001583107
“Interest expense in 2025 and 2024 represented non-cash interest expense associated with $25.0 million received from Royalty Pharma in July 2022 to partially fund our CYPRESS study.”
FILING10-K0001104659-26-033077cik 0001583107
“In 2025, we recognized a $75.1 million net gain on contingent milestone and royalty assets resulting from the sale of our TRELEGY royalties to GSK.”
FILING10-K0001104659-26-033077cik 0001583107
“In February 2026, we received a $50.0 million maximum milestone payment from Royalty Pharma Investments associated with the achievement of certain minimum royalty payments related to 2025 TRELEGY global net sales.”
FILING10-K0001104659-26-033077cik 0001583107
“Since its formation, the Committee has been working on an ongoing basis with Lazard, its independent financial advisor, to evaluate opportunities available to us, including under multiple potential outcomes for our Phase 3 CYPRESS study of ampreloxetine in patients with neurogenic orthostatic hypotension due to multiple system atrophy.”
FILING10-K0001104659-26-033077cik 0001583107
“Prior to the sale of VIBATIV to Cumberland Pharmaceuticals Inc. ("Cumberland") in November 2018, we had certain price reporting obligations to the Medicaid Drug Rebate program and other governmental pricing programs, and we had obligations to report average sales price under the Medicare program.”
FILING10-K0001104659-26-033077cik 0001583107
“Through the milestone payment we may receive from Royalty Pharma if certain TRELEGY global net sales thresholds are met following our sale of our economic interest in TRELEGY (the "Milestone Payments"), we may participate economically in royalty payments from GSK with respect to the TRELEGY.”
FILING10-K0001104659-26-033077cik 0001583107
Watchlist prices, news filtered to it, and its next report on your desk.
Theravance Biopharma, Inc. has 3 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Theravance Biopharma, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Theravance Biopharma, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
TBPH (Theravance Biopharma, Inc.) has 3 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: LAZ −2.99%, in financials.